Has Gene Voskuhl received payments from drug or device companies?

Yes. Drug and device makers reported $16,041 in general payments to Gene Voskuhl across 141 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Gene Voskuhl did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Gene Voskuhl come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Gene Voskuhl

Infectious Disease · Sherman, TXNPI 1649249392

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $11,910 of the $16,041 with a category attached, or 74.2%. Viiv Healthcare Company accounts for 88.1% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2020 at $8,069 and has fallen 96.6% since, to $274 in 2025. Among infectious disease clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$16,041in general payments, 2019–2025

Across 141 payments — averaging $113.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Viiv Healthcare Company$14K
Gilead$1K
Merck$371
Johnson & Johnson$138
Janssen Products, LP$70
Napo Pharmaceuticals Inc$47
plus $56 from 2 others

$69,443,748in research payments, 2019–2025

Across 251 payments — averaging $276,668 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$41.8M
Amgen$10.9M
Genentech, Inc.$5.2M
Apellis Pharmaceuticals, Inc.$3.5M
Merck$2.1M
F. Hoffmann-la Roche AG$1.5M
plus $4.4M from 5 others

What the payments were for

Consulting fees$11,91074%
Speaking & faculty fees$290%
Food & beverage$3,98525%
Education$1181%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Viiv Healthcare Company	73	$14,134
Gilead	42	$1,226
Merck	6	$371
Johnson & Johnson	12	$138
Janssen Products, LP	1	$70
Napo Pharmaceuticals Inc	3	$47
Janssen Scientific Affairs, LLC	2	$32
Theratechnologies Inc.	2	$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

DOVATO$4,722
DELSTRIGO$246
Epclusa$119
APRETUDE$102

How this compares

$16,041 in reported general payments places this provider in the 90th percentile of 576 infectious disease providers in Texas.

See all infectious disease providers in Texas →

Other infectious disease in Sherman

Elizabeth RaceDallas$1.5M
Ogechika AlozieEl Paso$834K
Joseph GatheHouston$695K
Roy ChemalyHouston$686K
Cedric SpakFort Worth$427K
Ben BarnettHouston$424K
Uriel SandkovskyDallas$320K
Amar SafdarHouston$284K
Roger BedimoDallas$269K
Miguel Sierra-HoffmanVictoria$238K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →